When: Price reaches $252-268 range on rally

Then: Execute tiered trim via limit orders

When: Price closes above $265 with MACD histogram higher high + RSI <70

Then: Upgrade to Hold

When: $200 closes on expanding volume + MACD acceleration

Then: Downgrade to Sell

SELL with 40-50% of benchmark weight (more aggressive than trader-proposed 60-70%); widen stop to $190 with daily close trigger or use 200 SMA break; raise cash rather than rotate into replacements; re-enter only on confirmed signals (hold $200-$205 zone, daily close above 10 EMA at $248, MACD histogram positive)

• Agrees with aggressive analyst on core diagnosis: EPS normalization distortion ($2.9B security gain inflating EPS from ~$1.65 to $4.29), hostile macro (95% probability of zero Fed cuts in 2026), failed Dreamforce catalyst, and technical deterioration (MACD histogram +5.72 to -2.30, lost 10 EMA at $248, RSI 82 to 57)
• Balance sheet risk warrants more aggressive de-risking: $24.8B new debt, equity shrank $61B to $38B YoY, interest expense surged from $67M to $473M quarterly (7x increase) and hasn't fully hit run rate
• Argues 60-70% trim still too much exposure when leading indicators deteriorating and lagging ones not confirmed
• Distinguishes between REDUCING RISK and MAKING A BEARISH BET—targeting drawdown to $199 over $300 is a short thesis, not capital preservation
• Warns against rotation into replacement names under pressure—introduces transaction cost drag, timing risk, and concentration risk in unknown names with unknown valuations
• Disputes sentiment interpretation—institutional accumulation often looks like distribution in early stages; consensus expecting deterioration creates risk of grinding sideways with compounding opportunity cost
• Technical: $200-$205 zone has structural support (50 SMA and 200 SMA convergence); stop loss at $200 too tight given daily ATR of $9.83 (~4% of price)
• Re-entry framework: hold reduced position if $200-$205 holds; add back if daily close above 10 EMA ($248) and MACD histogram turns positive; cut further if $200 breaks

→ vs aggressive: The aggressive analyst's claim that drawdown to $199 is 'much more probable than another leg to $300' is a directional call dressed as risk management—it's a short thesis, not capital preservation. Being confident about downside magnitude is precisely the overconfidence that gets conservative managers fired.

→ vs aggressive: The proposed rotation into 'cleaner balance sheets, less macro sensitivity, and earnings power that doesn't depend on one-time gains' introduces unpriced risk—unknown replacement names, entry timing risk, transaction costs, and concentration risk in whatever basket is chosen without disclosed valuations or leverage profiles.

→ vs aggressive: The sentiment reading of 'institutional bullishness plus retail silence plus price rejection' as textbook distribution is presented as certainty when institutional accumulation often looks identical in early stages; the aggressive analyst is presenting a directional view as established fact.

→ vs aggressive: The aggressive analyst did not address the stop loss at $200, which is problematic given daily ATR of $9.83 (~4%); a hard stop at $200 will likely be clipped by volatility noise before any meaningful support test plays out.

SELL at 60-70% benchmark weight with $200 daily close stop, hedge with $200 strike puts through November earnings, no new longs above $240, re-enter 75-80% on reclaim of $250 with MACD confirmation

• Supports SELL direction as asymmetric setup favors short side with EPS normalization, failed Dreamforce catalyst, deteriorating technicals (MACD rollover, lost 10 EMA), and hostile macro all reinforcing
• Trim magnitude of 60-70% of benchmark weight is appropriate—acknowledges fundamental quality while reducing position given leading indicator deterioration
• Thesis is under pressure, not broken—the $17.7B TTM FCF, 77% gross margins, and accelerating revenue from $44B base warrant continued exposure
• $200 daily close stop (not intraday) is the structural invalidation point at 50/200 SMA convergence zone
• Moderate trim and defined-risk hedges (put protection at $200 strike for November cycle) preferred over full rotation or full cash
• Q3 late November earnings is the real inflection point; everything before is positioning
• Re-entry framework: daily close above 10 EMA ($248) with MACD histogram turning positive and reclaim of $250 level triggers add-back to 75-80% benchmark weight
• Polymarket 95% probability of no cuts in 2026 is consensus already partially priced; real risk is Fed pivot tail or AI bookings surprise
• Aggressive analyst's rotation prescription is problematic—no replacement names named, no entry analysis, ignoring transaction cost drag and timing risk

→ vs aggressive: Presenting directional view as inevitability—prediction dressed as certainty; rotation prescription adds three new risk layers (replacement names, stretched valuations, transaction costs) without analysis

→ vs conservative: Throwing away fundamental quality—77% gross margins and $17.7B FCF is not a melting ice cube; cutting to 40-50% effectively says thesis is broken when data doesn't support that

→ vs conservative: Widening stop to $190 gives trade more room to work against you; original $200 stop is 18% below current price providing substantial cushion, and loosening further means tolerating full retracement of recovery move